Specifically, a S867A substitution at the conserved TBK1 phosphorylation site renders human NIK resistant to degradation,8 and immunoblot analysis of BT114 glioma cells confirmed that NIK(S867A) is expressed at higher levels than NIK(WT) (Figure 1a). Here, MAP3K14 is linked to central nervous system cancer.